The FDA has approved Enbumyst, a nasal spray formulation of bumetanide, for the treatment of edema associated CHF, and hepatic and renal disease.

The Global Oral Rinse Market is estimated to be valued at USD 7.25 Bn in 2025 and is expected to reach USD 12.03 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2025 to 2032.

Eight African countries, including Uganda, Kenya and Tanzania, participated in the review and committed to fast-tracking national approvals within 90 days NEWS ANALYSIS | BY AGENCIES | Every year, ...

Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA ApprovalKANSAS CITY, Kan., Sept.

Cingulate (CING) announced it has entered into a commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-1301, the ...

The National Pharmaceutical Pricing Authority (NPPA) has notified the retail price of nine new drugs, including three anti-inflammation fixed dose combinations (FDCs) and six antidiabetic combinations ...